StockNews.com upgraded shares of Agios Pharmaceuticals (NASDAQ:AGIO – Free Report) from a sell rating to a hold rating in a research note issued to investors on Wednesday. Several other analysts also recently weighed in on AGIO. Royal Bank of Canada reduced their target price on Agios Pharmaceuticals from $43.00 to $42.00 and set an outperform […]